Findings summarizing clinical evidence by indication (no explicit 'covered when' rules in this excerpt):
Glioblastoma (dural metastasis & newly diagnosed): Small case series and feasibility reports suggest SRS may produce radiographic responses in select dural GBM metastases and that fractionated approaches have been used experimentally for newly diagnosed GBM; evidence is limited and further trials are needed.
Hintenlang et al: single-case dural metastasis treated with 20 Gy in 1 fraction showing near-complete resolution at 6 months.
Oligometastatic colorectal cancer: Systematic reviews report 1- and 2-year local control ranges for liver (50–100% at 1 year; 32–91% at 2 years) and lung (62–92% at 1 year; 53–92% at 2 years); BED ranges widely; data are promising but not yet mature.
Kobiela et al systematic review.
Cerebral cavernous malformations: A systematic review of 30 cohort studies (n=1,576) found annual incidences after SRS of death 0.18%, intracerebral hemorrhage 2.40%, and persistent focal neurologic deficit 0.71%; outcomes appear comparable to non-SRS management but randomized trials are needed.
Poorthuis et al systematic review.
Incidental meningiomas: Meta-analysis demonstrated significantly higher tumor control with SRS versus observation over mean follow-up >3 years with acceptable morbidity; risk factors for progression include MRI T2 hyperintensity, larger initial diameter, and absence of calcification.
Zhang and Zhang systematic review and meta-analysis.
Pituitary adenomas (secretory): Meta-analysis shows high pooled tumor control rates for secretory pituitary adenomas but lower endocrine remission rates and a measurable risk of new hypopituitarism.
Mathieu et al systematic review: tumor control rates high (eg, acromegaly 97%), endocrine remission lower (eg, acromegaly 44%).
Small cell lung cancer (T1-2N0M0) treated with SABR: Meta-analysis of SABR for early node-negative SCLC reports 1-year local control ~97.3% and 1-year overall survival ~86.3% with limited high-grade toxicity reported.
Safavi et al systematic review/meta-analysis.
Vestibular schwannomas: Systematic reviews and a large multicenter retrospective cohort report high tumor control (≈89–94%) after SRS for Koos grade-IV tumors; facial nerve risk associates with higher margin dose and a recommended margin dose <13 Gy to reduce facial palsy risk.< 13 Gy
Dumot et al and related analyses report tumor control ~94.1% and facial nerve risk with margin dose ≥13 Gy.
Medial thalamotomy for intractable pain: Systematic review shows initial meaningful pain reduction in a proportion of patients with some persistent benefit but variable durability; adverse events are relatively uncommon.
Aggregate initial meaningful pain reduction ~55%, persistent effect ~38%.
Oligometastatic breast and renal cell cancers: Phase II SBRT for lung/liver oligometastases in breast cancer reported excellent tolerability with no grade 3–4 toxicities; retrospective SABR series in oligometastatic RCC suggest possible benefit when delivered early but are limited by small sample sizes.
Franceschini et al (breast SBRT) and Ma et al (RCC retrospective SABR).